Home › Multiple Myeloma › Missouri › St. Louis
Pag-aaral pangklinika para sa Multiple Myeloma sa St. Louis, MO
24 pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng St. Louis (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Washington University School Of Medicine, St Louis
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Nagre-recruitPhase 1/2
- Washington University School of Medicine, St Louis
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Nagre-recruitPhase 4
- Washington University School Of Medicine, St Louis
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Nagre-recruitPhase 1
- Research Site, St Louis
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Washington University School Of Medicine, St Louis
Collection of Tissue Samples for Cancer Research
Nagre-recruitObservasyonal na pag-aaral
- Washington University - St. Louis, St Louis
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Washington University School of Medicine, St Louis
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Nagre-recruitPhase 3
- Washington University School of Medicine, St Louis
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
- Research Site, St Louis
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Nagre-recruitPhase 2
- GSK Investigational Site, Bridgeton · 15 mi ang layo
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Nagre-recruitPhase 3
- Mercy Infusion Center - Chippewa, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- at 4 pa
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Nagre-recruitPhase 3
- Research Site, St Louis
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Nagre-recruitPhase 2
- Washington University School of Medicine, St Louis
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Washington University/Siteman Cancer Center, St Louis
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Nagre-recruitPhase 1
- Washington University School of Medicine, St Louis
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Nagre-recruit
- Washington University School of Medicine, St Louis
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Nagre-recruitPhase 1
- Washington University School of Medicine, St Louis
64Cu-LLP2A for Imaging Hematologic Malignancies
Nagre-recruitMaagang Phase 1Malugod na tinatanggap ang malusog na boluntaryo
- Washington University School of Medicine, St Louis
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Nagre-recruitPhase 3
- Saint Louis Cancer and Breast Institute-South City, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- at 5 pa
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Nagre-recruitPhase 1
- Washington University School of Medicine, St Louis
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Nagre-recruit
- Washington University School of Medicine, St Louis
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Washington University /ID# 266972, St Louis
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Nagre-recruitPhase 3
- Saint Louis University, St Louis
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Nagre-recruitPhase 1
- Washington University School of Medicine, St Louis
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY60 pag-aaral
- Boston, MA42 pag-aaral
- Atlanta, GA42 pag-aaral
- Houston, TX38 pag-aaral
- Durham, NC37 pag-aaral
- Nashville, TN32 pag-aaral
- Denver, CO27 pag-aaral
- Rochester, MN24 pag-aaral
- Columbus, OH24 pag-aaral
- Baldwin Park, CA23 pag-aaral
- Edison, NJ22 pag-aaral
- Chicago, IL22 pag-aaral
Iba pang pag-aaral sa St. Louis
- Non-Small Cell Lung Cancer73 pag-aaral
- Kanser sa Suso64 pag-aaral
- Metastatic Cancer54 pag-aaral
- Colorectal Cancer50 pag-aaral
- Kanser (lahat ng uri)46 pag-aaral
- Kanser sa Prostate46 pag-aaral
- Kanser sa Baga39 pag-aaral
- Kanser sa Ovary38 pag-aaral
- Kanser sa Pancreas33 pag-aaral
- Kanser ng Endometrium29 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg28 pag-aaral
- Pagkabigo ng Puso26 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.